Résumé
What is this summary about? This is a plain language summary of a clinical study of a medicine called lowsodium oxybate (or LXB, also known as Xywav (R)) in adults with idiopathic hypersomnia. Idiopathic hypersomnia is a rare sleep disorder that makes people have extreme sleepiness during the day. It also can make them sleep a long time at night and during the day, and make it hard for them to fully wake up. This study looked at changes in idiopathic hypersomnia symptoms after participants took LXB for 12 to 16 weeks, and then either switched to placebo for 2 weeks or kept taking LXB for 2 more weeks. The placebo did not contain any medicine, but it looked and tasted like LXB. By comparing results from the placebo and LXB groups, researchers could see if LXB helped symptoms of idiopathic hypersomnia, as well as the impacts of those symptoms on day-to-day functioning and quality of life. What is this summary about? What were the results? In this study, excessive daytime sleepiness and other symptoms of idiopathic hypersomnia (like prolonged sleep and sleep inertia), and the impacts of these symptoms on day-to-day functioning and quality of life, got worse for participants who switched from LXB to placebo compared with those who kept taking LXB. In other words, LXB helped treat symptoms of idiopathic hypersomnia, including excessive daytime sleepiness. The most common side effects were nausea, headache and dizziness. What do the results mean? LXB reduced excessive daytime sleepiness and other symptoms (like prolonged sleep and sleep inertia) in participants with idiopathic hypersomnia, and also improved their day-to-day functioning and quality of life.